Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research

Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research




ADELAIDE, AUS, Sept 24, 2021 – (ACN Newswire) – Agilex Biolabs, Australia’s most skilled and highly advanced bioanalytical lab and the only biolab in the area with a devoted toxicology system, has actually been picked as a finalist for the Most Successful Early Phase Research (Preclinical & Phase I) classification in the Citeline Awards 2021.

The Citeline Awards were produced to acknowledge achievements throughout the biopharmaceutical market, offering a chance for the market to honor its greatest achievers. Accomplishments throughout the spectrum of crucial R&D activities are commemorated, from successes in early and late-stage research study, to advances in technological tools, to developments in trial style and execution.

Agilex Biolabs uses innovative bioanalytical services for biotech business and provides toxicology services to support pre-clinical and early stage research study within their TetraQ, department.

Dr. Peter Tapley, Director Toxicology at TetraQ, stated the research study sent for the Citeline Award concentrated on preclinical evaluation of the security and tolerability of a SARS-CoV-2 Sclamp protein subunit COVID-19 vaccine in rats.

” The preclinical toxicity research studies carried out by TetraQ were needed to make it possible for the fast approval and safe development of the unique SARS-CoV-2 Sclamp subunit vaccine into medical screening in healthy volunteers,” he stated.

” This research study highlights the paths that biotech business can consider quick vaccine advancement, and how the Australian research study, regulative and scientific facilities supplies an encouraging environment.”

The TetraQ security research studies carried out in assistance of the vaccine advancement were referenced in Watterson et al ‘Preclinical advancement of a molecular clamp-stabilised subunit vaccine for serious intense breathing syndrome coronavirus 2’ Clin Transl Immunology. 2021 Apr 5;-LRB- ( 4 ): e1269 doi: 10.1002/ cti2.1269 eCollection2021 The crucial contributions of TetraQ to the program were acknowledged by the addition of Drs. Brockman, Tran and Tapley as co-authors.

A description of the medical research study helped with by the preclinical toxicity research study program was reported in Chappell et al ‘Safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, stage 1 trial’ Lancet Infect Dis. 2021 Apr 19; S1473-3099(21)00200 -0. doi: 10.1016/ S1473-3099(21)00200 -0. This publication likewise consisted of recommendation to vaccine serum antibody titre analyses performed by Agilex Biolabs to support the medical program. This contribution was acknowledged by the addition of Drs Tran and Tapley as co-authors. The advancement of this variation of the SARS-CoV-2 Sclamp vaccine was eventually stopped the scientific research study showed the capacity of the Sclamp vaccine innovation.

The COVID-19 pandemic has actually seen the fast advancement of a series of unique vaccines targeting SARS-CoV-2 in Australia, assisted in by the accessibility of top quality agreement research study companies such as Agilex Biolabs, and a beneficial regulative environment.

Agilex Biolabs’ TetraQ department uses a series of toxicology services to support early to late phase advancement programs. These services consist of exploratory toxicology and pharmacokinetics research studies and GLP toxicology services. Research studies needing non-rodent types consisting of pets and non-human primates are carried out by means of our partner laboratories. Research studies are likewise supported by Agilex Biolabs’ world class bioanalytical and immunoassay services.

Agilex Biolabs provides services for both little particles and biologics for PK, immunogenicity (PD) and biomarker bioanalysis using the 2 platforms of LC-MS/MS and Immunoassay.

Agilex Biolabs’ first-rate immunoassay and immunobiology labs include advanced devices consisting of Gyrolab Xplore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 circulation cytometer and quickly to be launched, digital bead quantitative real-time RT-PCR.

Australian medical trials have actually stayed open for company and Agilex Biolabs is a designated important service so customers can be ensured of research study connection.

Agilex Biolabs has more than 140 personnel that includes 85 devoted lab personnel, and supports customer pharma and biotech business from United States, Europe and APAC.

The 2021 Citeline Awards will happen October 14, 2021 in Boston, MA, USA.

Book a private rundown with our researchers prior to you begin your next scientific trial. https://calendly.com/agilexbiolabs/30 minutes

About Agilex Biolabs https://www.agilexbiolabs.com/

Agilex Biolabs, the Australian professional bioanalytical and toxicology lab centers for medical trials, has more than 24 years’ experience in carrying out managed bioanalysis, consisting of quality technique advancement, approach recognition and sample analysis services. It has actually effectively supported numerous preclinical and medical trials from worldwide where qualified clients select Australia for the structured regulative procedure, quality information and access to the world’s most appealing R&D refund of as much as 43.5%on both nonclinical and medical trial work carried out in Australia.

Agilex Biolabs likewise provides toxicology services through TetraQ an Agilex Biolabs business, a recognized GLP toxicology center in Australia.

Agilex Biolabs has the leading accreditations consisting of OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance keeping an eye on authority) and ISO 17025 Accreditation for international acknowledgment.

The business has actually just recently broadened its primary laboratories by more than 30%to accommodate biotech need from APAC and the USA. In addition Agilex Biolabs has actually introduced a brand-new Immunobiology laboratory – view the video here. https://www.agilexbiolabs.com/launch-of-immunobiology-laboratory/

Agilex Biolabs specialises in bioanalysis of little particles and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics evaluations using LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and circulation cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex deals pharmacodynamics services that consist of immunobiology services utilizing the most recent advanced innovation to support immunology, cell biology and mode of action assays, consisting of:

– Immunophenotyping

– Receptor tenancy

– Cytokine release assays (entire blood or PBMC stimulation assays) and cytokine/biomarker profiling

– PBMC assays and cellular system of action assays

Agilex Biolabs Media Contact:

Kate Newton

Media@AgilexBiolabs.com


Topic: Awards



Source: Agilex Biolabs


Sectors: Healthcare & Pharm, Clinical Trials


http://www.acnnewswire.com


From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights scheduled. A department of Asia Corporate News Network.


Read More

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *